Works matching IS 11727047 AND DT 2022 AND VI 36 AND IP 1

Results: 11

Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy.

Published in:

2022

By:

Hoy, Sheridan M.

Publication type:

Correction Notice

Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.

Published in:

CNS Drugs, 2022, v. 36, n. 1, p. 45, doi. 10.1007/s40263-021-00887-w

By:

Jakimovski, Dejan;
Awan, Samreen;
Eckert, Svetlana P.;
Farooq, Osman;
Weinstock-Guttman, Bianca

Publication type:

Article

Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain.

Published in:

2022

By:

Petzke, Frank;
Tölle, Thomas;
Fitzcharles, Mary-Ann;
Häuser, Winfried

Publication type:

journal article

Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia.

Published in:

CNS Drugs, 2022, v. 36, n. 1, p. 1, doi. 10.1007/s40263-021-00884-z

By:

Mould, Arne W.;
Al-Juffali, Noura;
von Delft, Annette;
Brennan, Paul E.;
Tunbridge, Elizabeth M.

Publication type:

Article

Authors' Reply to Ulrich: Comment on 'Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use Them Safely and Effectively'.

Published in:

2022

By:

Baldwin, David S.;
Chamberlain, Samuel R.

Publication type:

Letter

Comment on: "Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively".

Published in:

2022

By:

Ulrich, Sven

Publication type:

Letter

Correction to: Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.

Published in:

2022

By:

Chamberlain, Samuel R.;
Baldwin, David S.

Publication type:

Correction Notice

Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials.

Published in:

CNS Drugs, 2022, v. 36, n. 1, p. 61, doi. 10.1007/s40263-021-00886-x

By:

Meskill, Gerard J.;
Davis, Craig W.;
Zarycranski, Donna;
Doliba, Markiyan;
Schwartz, Jean-Charles;
Dayno, Jeffrey M.

Publication type:

Article

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.

Published in:

CNS Drugs, 2022, v. 36, n. 1, p. 17, doi. 10.1007/s40263-021-00877-y

By:

Ling, Susan;
Ceban, Felicia;
Lui, Leanna M. W.;
Lee, Yena;
Teopiz, Kayla M.;
Rodrigues, Nelson B.;
Lipsitz, Orly;
Gill, Hartej;
Subramaniapillai, Mehala;
Mansur, Rodrigo B.;
Lin, Kangguang;
Ho, Roger;
Rosenblat, Joshua D.;
Castle, David;
McIntyre, Roger S.

Publication type:

Article

Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study.

Published in:

CNS Drugs, 2022, v. 36, n. 1, p. 83, doi. 10.1007/s40263-021-00875-0

By:

Palmeri, Serena;
Ponzano, Marta;
Ivaldi, Federico;
Signori, Alessio;
Lapucci, Caterina;
Casella, Valentina;
Ferrò, Maria Teresa;
Vigo, Tiziana;
Inglese, Matilde;
Mancardi, Giovanni Luigi;
Uccelli, Antonio;
Laroni, Alice

Publication type:

Article

Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder.

Published in:

CNS Drugs, 2022, v. 36, n. 1, p. 71, doi. 10.1007/s40263-021-00870-5

By:

Ilic, Katarina;
Kugler, Alan R.;
Yan, Brian;
McNamara, Nora

Publication type:

Article